- Conditions
- Adenocarcinoma, Bile Duct Diseases, Bile Duct Neoplasms, +14 more
- Locations
-
- Anhui Provincial Hospital ( Site 0140) Hefei, Anhui, China
- Beijing Cancer Hospital ( Site 0138) Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital ( Site 0150) Beijing, Beijing Municipality, China
- First Affiliated Hospital of The Third Military Medical University ( Site 0130) Chongqing, Chongqing Municipality, China
Clinical trial condition
Biliary Tract Carcinoma
Explore clinical trials studying Biliary Tract Carcinoma. Study availability and eligibility vary by location and protocol.
17 public trials
6 recruiting studies
Biliary Tract Carcinoma trial results
NCT04003636
- Conditions
- Adenocarcinoma, Bile Duct Diseases, Bile Duct Neoplasms, +14 more
- Locations
-
- University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016) Birmingham, Alabama, United States
- University of California San Diego Moores Cancer Center ( Site 0008) La Jolla, California, United States
- UCLA Hematology/Oncology - Santa Monica ( Site 0014) Los Angeles, California, United States
- University of California - San Francisco ( Site 0030) San Francisco, California, United States
Completed
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
NCT04067960
- Conditions
- Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, +82 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
Completed
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
NCT03027284
- Conditions
- Adenocarcinoma, Advanced Cancer, Biliary Tract Carcinoma, +27 more
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Chiba, Japan
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Tokyo, Japan
NCT00490399
- Conditions
- Biliary Tract Carcinoma
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Seoul, South Korea
Active, Not Recruiting
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
NCT06048133
- Conditions
- Adenocarcinoma, Bile Duct Cancer, Bile Duct Diseases, +12 more
- Locations
-
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
- University of Michigan Health System Ann Arbor, Michigan, United States
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
- University of Wisconsin Madison, Wisconsin, United States
Active, Not Recruiting
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02151084
- Conditions
- Biliary Tract Carcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +11 more
- Locations
-
- Princess Margaret Cancer Centre Toronto, Ontario, Canada